Newsroom

Healthcare Pharmaceutical Biotech

Stay informed with the latest in Healthcare, Pharmaceutical and Biotech press releases through our newsroom. Explore breaking updates, industry trends, and insights shaping these vital sectors—all in one place. Whether it’s innovation, regulatory changes, or breakthroughs, our newsroom keeps you connected to the stories that matter most.


Latest Press Releases

Medical Care Technologies Inc. (OTC PINK:MDCE) 2026 Annual Shareholder Update and Strategic Roadmap
Healthcare & PharmaceuticalCompany Update

Medical Care Technologies Inc. (OTC PINK:MDCE) 2026 Annual Shareholder Update and Strategic Roadmap

January 12, 2026 9:30 AM

Medical Care Technologies Inc. (OTC PINK:MDCE) ("MDCE" or the "Company"), a technology-focused company developing AI-driven consumer, wellness, and medical applications, today provided its 2026 annual shareholder update outlining its short-term, near-term, and long-term strategic goals as the Company advances its next phase of growth. These updates are also updated on our corporate website www.medicalcaretechnologies.com. Short-Term Goals...

Read more
MDaudit Recognized as One of Modern Healthcare's Best in Business
Healthcare & PharmaceuticalAwards

MDaudit Recognized as One of Modern Healthcare's Best in Business

January 12, 2026 9:05 AM

MDaudit, an award-winning cloud-based continuous risk monitoring platform for healthcare revenue cycle management, is honored to be recognized by Modern Healthcare as one of the Best in Business of 2025. The annual program celebrates organizations that drive innovation, efficiency, and excellence, highlighting their pivotal role in enhancing the overall healthcare ecosystem. "We are proud to honor this year's recipients of Modern Healthcare's...

Read more
US Med-Equip Recognized as One of Modern Healthcare's Best in Business
Healthcare & PharmaceuticalAwards

US Med-Equip Recognized as One of Modern Healthcare's Best in Business

January 12, 2026 9:00 AM

US Med-Equip (USME) was named one of Modern Healthcare's Best in Business and featured in this month's publication for helping hospitals with its on-demand medical equipment rentals and management solutions. Modern Healthcare, the most trusted business news in the healthcare industry empowering healthcare leaders to make informed business decisions, recognized USME as part of its distinguished 2025 list of "leading healthcare suppliers, vendors...

Read more
Jaguar Health Enters into U.S. License Agreement with Future Pak for Crofelemer, Providing up to $38 Million
Healthcare & PharmaceuticalCompany Update

Jaguar Health Enters into U.S. License Agreement with Future Pak for Crofelemer, Providing up to $38 Million

January 12, 2026 9:00 AM

Jaguar Health, Inc. (NASDAQ:JAGX) today announced that its wholly-owned subsidiary Napo Pharmaceuticals, Inc. (collectively, with Jaguar Health, Inc., "Jaguar") has entered into a U.S. licensing agreement with an affiliate of privately held Future Pak, LLC ("Future Pak"). Under the terms of the agreement, Future Pak will be the exclusive marketer for Mytesi (crofelemer), Jaguar's FDA-approved novel prescription drug for the symptomatic relief of...

Read more
CASI Pharmaceuticals Announces Update and Additional Results from Phase 1 Study of CID-103 in Adult Patients with Chronic Immune Thrombocytopenia
Healthcare & PharmaceuticalCompany Update

CASI Pharmaceuticals Announces Update and Additional Results from Phase 1 Study of CID-103 in Adult Patients with Chronic Immune Thrombocytopenia

January 12, 2026 9:00 AM

CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company developing CID-103, a potentially best-in-class, anti-CD38 monoclonal antibody, for patients with organ transplant rejection and autoimmune diseases, today announced additional data from its Phase 1 open-label study of CID-103 in adult patients with immune thrombocytopenia (ITP). Initial clinical data from this study were presented at the 67th American Society...

Read more
VSee Launches AI-Driven Rural Health Transformation Platform, Targeting Millions in Recaptured Revenue Per Hospital
Healthcare & PharmaceuticalProduct Announcements

VSee Launches AI-Driven Rural Health Transformation Platform, Targeting Millions in Recaptured Revenue Per Hospital

January 12, 2026 8:19 AM

VSee Health, Inc. (Nasdaq:VSEE) today announced the launch of its AI‑enhanced Rural Health Transformation Solution, a modular platform designed to help rural hospitals expand specialty access, improve clinical outcomes, and strengthen financial performance-without increasing fixed staffing costs. The launch comes soon after the Centers for Medicare & Medicaid Services (CMS) recent announcement of funding awards for all 50 states through the...

Read more
Ozempic Face and Loose Skin Surge Drives DMV Patients to The Naderi Center's Advanced Non-Surgical & Surgical Treatments
Healthcare & PharmaceuticalCompany Update

Ozempic Face and Loose Skin Surge Drives DMV Patients to The Naderi Center's Advanced Non-Surgical & Surgical Treatments

January 12, 2026 8:00 AM

As rapid weight-loss medications such as Ozempic and Wegovy become increasingly popular, patients across the Washington, DC metropolitan area are noticing unexpected side effects: sudden facial volume loss, loose skin, and accelerated signs of aging. The Naderi Center for Plastic Surgery & Dermatology, with offices in Chevy Chase, Maryland-near Washington, DC-and Reston, Virginia, is seeing a dramatic rise in patients seeking expert guidance and...

Read more
Aytu BioPharma Details Agenda for Investor Day Scheduled for January 20, 2026 in New York City
Healthcare & PharmaceuticalConferences

Aytu BioPharma Details Agenda for Investor Day Scheduled for January 20, 2026 in New York City

January 12, 2026 8:00 AM

DENVER, CO / ACCESS Newswire / January 12, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, today provided additional details for its upcoming Investor Day, scheduled for Tuesday, January 20, 2026, at 11:00 a.m. Eastern time in New York City. The Investor Day will be both...

Read more
GridAI: The Grid Is the New Battleground for AI Economics
Healthcare & PharmaceuticalCompany Update

GridAI: The Grid Is the New Battleground for AI Economics

January 12, 2026 8:00 AM

For years, investors were trained to believe the bottleneck in artificial intelligence would be chips. Then it was talent. Then it was data. Each time, the market adjusted, capital flowed, and new winners emerged. What has changed quietly, but decisively, is where that constraint now lives. Electricity. Not electricity in the abstract sense of power generation, but in the operational sense of when energy is available, where it can flow, and how...

Read more
TRTInjections.com Launches to Simplify TRT Education for Clinics and Patients
Healthcare & PharmaceuticalCompany Update

TRTInjections.com Launches to Simplify TRT Education for Clinics and Patients

January 12, 2026 7:35 AM

TRTInjections.com announced today the public launch of its new educational platform built to help TRT clinics and TRT users quickly access clear, practical injection guidance in one place. Designed for busy providers and real world patients alike, the site delivers a streamlined experience that makes it easier to learn proper injection site selection, understand rotation basics, and follow consistent technique standards without wading through...

Read more
OBI Pharma and TegMine Therapeutics Sign Exclusive Global License Agreement for Glycan-Targeting ADC
Healthcare & PharmaceuticalPartnerships

OBI Pharma and TegMine Therapeutics Sign Exclusive Global License Agreement for Glycan-Targeting ADC

January 12, 2026 7:00 AM

OBI Pharma (4174.TWO) announced that it has entered into a commercial license agreement with TegMine Therapeutics, Inc. (TegMine), a San Francisco-based biopharma focused on developing antibodies targeting cancer-associated glycans and glycoproteins, for a glycan-targeting ADC. Under the terms of the agreement, OBI is eligible to receive an upfront payment as well as development and commercial milestones. Following product launch, OBI will also...

Read more
Moderna Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference
Healthcare & PharmaceuticalConferences

Moderna Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference

January 12, 2026 7:00 AM

Moderna, Inc. (NASDAQ:MRNA) today announced business updates and progress across its pipeline of mRNA medicines. Moderna enters 2026 with a focus on growing sales, launching new infectious disease products and delivering pivotal readouts across oncology, rare disease and infectious disease portfolios. "In 2025, we strengthened our commercial execution, successfully launched our third product, and continued to advance our mRNA pipeline. At the...

Read more
Black Book Research Releases 2026 State of South Korean Acute Care EMR Digital Adoption Report
Healthcare & PharmaceuticalPartnerships

Black Book Research Releases 2026 State of South Korean Acute Care EMR Digital Adoption Report

January 12, 2026 7:00 AM

Black Book Research today announced the release of its 2026 State of South Korean Acute Care EMR Digital Adoption report, a stakeholder-validated strategic fit assessment of seven core acute-care EMR/HIS/EHR platforms and six enabling ecosystem platforms across four provider segments and 18 qualitative strategic fit dimensions over the 2026-2030 planning horizon. South Korea's acute-care market, among the most digitally mature globally, has...

Read more
Amphastar Pharmaceuticals Announces Exclusive License Agreement with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. for Fully Synthetic Corticotropin Compound
Healthcare & PharmaceuticalCompany Update

Amphastar Pharmaceuticals Announces Exclusive License Agreement with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. for Fully Synthetic Corticotropin Compound

January 12, 2026 6:00 AM

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) today announced that it has entered into an exclusive license agreement (the "Agreement") with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. ("Hanxin") for the development, and commercialization of a fully synthetic and highly purified human adrenocorticotropic hormone (ACTH) analogs (also termed corticotropin), now designated AMP-110, in the United States and Canada. AMP-110 is designed to...

Read more
Monthly Update December - A Year of Breakthroughs, Expansion and International Consolidation
Healthcare & PharmaceuticalCompany Update

Monthly Update December - A Year of Breakthroughs, Expansion and International Consolidation

January 12, 2026 5:20 AM

iZafe Group (STO:IZAFE-B) - As we summarize December and at the same time leave 2025 behind, it is clear that the year has been one of the most transformative in iZafe Group's history. We have taken clear steps from growth toward scalable expansion, with increased demand, a stronger partner network, and establishment in new markets. We have continued to build on our success in Sweden while simultaneously laying the foundation for something even...

Read more
CelLBxHealth PLC Announces Board Changes
Healthcare & PharmaceuticalRegulatory

CelLBxHealth PLC Announces Board Changes

January 12, 2026 2:10 AM

CelLBxHealth plc (AIM:CLBX), a leader in circulating tumour cell (CTC) intelligence, with tests and services supporting research, drug development and clinical oncology, is pleased to announce that further to the announcement of 15 December 2025, that the following have been appointed to the board with immediate effect: Peter Collins as Chief Executive Officer Klaas de Boer as Non-Executive Director Kim Oreskovic as Non-Executive Director...

Read more
Pre-JPM Investor Pulse Signals 2026 Capital Rotation Toward
Healthcare & PharmaceuticalConferences

Pre-JPM Investor Pulse Signals 2026 Capital Rotation Toward "AI That Ships," Admin Cost Takeout, and Differentiated Metabolic Assets With Special-Situations Capital Back in Scope

January 11, 2026 10:15 AM

Black Book Market Research today published a preliminary, directional preview of a Pre-JPM Investor Pulse, designed to quantify what venture capital, private equity, and investment banking participants are most actively seeking to fund, advise, acquire, or syndicate during JPM Week 2026 (Jan. 12-15). The preview summarizes modeled/indicative findings based on early outreach patterns and a targeted respondent mix of 88 industry investors....

Read more
Olympian Gabby Thomas Draws Crowd at Wellness Event with BetterWay(TM) Blood Testing at H-E-B SoCo
Healthcare & PharmaceuticalCompany Update

Olympian Gabby Thomas Draws Crowd at Wellness Event with BetterWay(TM) Blood Testing at H-E-B SoCo

January 10, 2026 6:15 PM

BetterWay™ blood testing by Babson Diagnostics, a science-first healthcare technology company transforming diagnostic blood testing, hosted Olympic gold medalist and public health advocate Gabby Thomas at H-E-B's iconic South Congress store on Saturday, January 10 for Live Well Your Way Day. The free-admission, community-focused event attended by hundreds launched BetterWay's Track Like Gabby™ powered by BetterWay™ campaign, an initiative to...

Read more
Best Weight Loss Pills for 2026: FDA Approves First Oral GLP-1 and What It Means for Patients
Healthcare & PharmaceuticalAdvertorial

Best Weight Loss Pills for 2026: FDA Approves First Oral GLP-1 and What It Means for Patients

January 10, 2026 4:15 PM

The phrase best weight loss pills for 2026 reflects common consumer search behavior and is used here to evaluate treatment options, access pathways, and decision criteria. It does not imply endorsement, ranking, or medical recommendation. This analysis reviews publicly available data to help readers independently assess weight loss medication options. Disclaimer: This article is for informational purposes only and does not provide medical...

Read more
Direct Meds Explained: What Consumers Should Know About Compounded Semaglutide and Tirzepatide via Telehealth
Healthcare & PharmaceuticalAdvertorial

Direct Meds Explained: What Consumers Should Know About Compounded Semaglutide and Tirzepatide via Telehealth

January 9, 2026 11:35 PM

Affiliate Disclosure: This article contains affiliate links. If you purchase through these links, a commission may be earned at no additional cost to you. This compensation does not influence the accuracy or integrity of the information presented. This article is for informational purposes only and does not constitute medical advice. GLP-1 medications are prescription drugs that require evaluation by qualified healthcare professionals. Always...

Read more

Join the thousands of ACCESS Newswire customers today who are getting millions of views on their news.


Check out our flexible subscription and pay as you go pricing

and packages.

Use Code NEWS10 for 10% off  of your first purchase.


Latest Blog Posts

Visit our blogs for press release tips, media engagement

Strategies, and Product Comparisons.

Executive delivering prepared remarks from an earnings call script
By Jennifer Hammers • July 9, 2026
How to write earnings call prepared remarks that land — structure, length, the safe-harbor open, non-GAAP language, and building remarks around your strategy.
IR
By Brian Balbirnie • July 8, 2026
A practical earnings call preparation checklist for IR teams — the two-week runway, consensus, logistics, Q&A prep, and Reg FD-clean disclosure timing.
ACCESS Newswire guide on AI investor relations — how AI assistants read company earnings disclosures
By Jennifer Hammers • July 6, 2026
AI assistants read your earnings within minutes. Learn how IR teams make disclosures AI-readable — and how the LLM Citation Score measures your visibility.
What does Meltwater cost in 2026, and what are the alternatives? Meltwater resells press release dis
By Jennifer Hammers • June 22, 2026
What does Meltwater cost in 2026, and what are the alternatives? See how ACCESS Newswire compares on distribution, data, and price.
A logo for accesswire next to a logo for rack
By Jennifer Hammers • June 21, 2026
Compare Muck Rack vs ACCESS Newswire on pricing, features, and alternatives. See how ACCESS Newswire adds distribution, pitching, and analytics.
A blue and white logo with a check mark next to it
By Jennifer Hammers • June 19, 2026
Compare Business Wire vs ACCESS Newswire on pricing and capabilities — and how ACCESS delivers comparable reach at a fraction of the cost.
Show More




Discover the news
by Industry:


Need help with your PR Strategy?
Learn more about our
professional PR Services today:

.MEDIA PRO 
Want to get noticed
by the Media but don’t
know how? 

.TOTAL PRO

Need full support to 

Optimize your PR

Efforts?